Zhejiang Jinxin Pharmaceutical Co., Ltd. Announcement of Resolutions of the Fourth Meeting of the Ninth Board of Directors
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed in this announcement, and are free from any false records, misleading statements, or material omissions.
Zhejiang Jinxin Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") convened the fourth meeting of the ninth Board of Directors on April 22, 2026, in the conference room on the first floor of the administrative building. The meeting notice was sent via email on April 10, 2026. Nine directors were expected to attend, and seven directors were present. Director Wang Nengneng authorized Director Hong Yunfei to attend, and Independent Director Lei Ying authorized Independent Director Xu Pan to attend. Senior management personnel of the Company attended the meeting. The meeting complied with the relevant provisions of the "Company Law" and the "Articles of Association." The meeting was presided over by Chairman Lü Gang, and the following resolutions were formed through voting:
I. With 9 votes in favor, 0 votes against, and 0 abstentions, the "2025 President's Work Report" was deliberated and approved.
II. With 9 votes in favor, 0 votes against, and 0 abstentions, the "2025 Board of Directors' Work Report" was deliberated and approved. This proposal needs to be submitted to the Company's 2025 Shareholders' Meeting for deliberation. For detailed content, please refer to the relevant content in "Section III, Management Discussion and Analysis" and "Section IV, Corporate Governance, Environment, and Society" of the "2025 Annual Report" published on the Juchao Information Network at http://www.cninfo.com.cn.
Independent Directors Lei Ying, Xu Pan, Huang Tao, and Zhang Daliang (whose term has expired and resigned) submitted their self-assessment reports to the Board of Directors and will present their reports at the Company's 2025 Shareholders' Meeting.
III. With 9 votes in favor, 0 votes against, and 0 abstentions, the "2025 Annual Report and Summary" was deliberated and approved. This proposal needs to be submitted to the Company's 2025 Shareholders' Meeting for deliberation. The full text of the annual report can be found on the Juchao Information Network at http://www.cninfo.com.cn; the summary of the annual report can be found in the announcement published by the Company in the "Securities Times," "China Securities Journal," and on the Juchao Information Network at http://www.cninfo.com.cn (Announcement No.: 2026016).
IV. With 9 votes in favor, 0 votes against, and 0 abstentions, the "2025 Financial Final Accounts Report" was deliberated and approved. This proposal needs to be submitted to the Company's 2025 Shareholders' Meeting for deliberation.
In 2025, the Company's total operating revenue was 4.069 billion yuan, a year-on-year decrease of 2.14%; the net profit attributable to shareholders of the listed company was 758 million yuan, a year-on-year increase of 6.46%; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 712 million yuan, a year-on-year increase of 10.06%, indicating an improvement in profitability.